反话
发表于 2025-3-23 09:58:45
http://reply.papertrans.cn/47/4624/462312/462312_11.png
躺下残杀
发表于 2025-3-23 15:43:39
http://reply.papertrans.cn/47/4624/462312/462312_12.png
浓缩
发表于 2025-3-23 21:21:21
Interferon and Tumor Necrosis Factor in Renal Cell Carcinoma Model Systems30% of patients with RCC have metastases at the time of diagnosis . Furthermore, metastases develop in a majority of untreated patients within 1 year after discovery. Advanced RCC is refractory to nearly all forms of systemic therapy. Hormonal therapy may result in a small proportion (0%–10%) of
暂时中止
发表于 2025-3-23 22:58:49
http://reply.papertrans.cn/47/4624/462312/462312_14.png
搜寻
发表于 2025-3-24 04:38:25
Treatment of Renal Cell Carcinoma with Interferone the efficacy of IFN- α in RCC has been tested in numerous studies. Recently the two other IFN, namely IFN-β and IFN-γ, have also been used in the treatment of RCC. Although we know much more about the subtypes and the action of IFN today than we did in 1983, the exact mechanisms of tumor control b
regale
发表于 2025-3-24 08:21:33
Combination Therapy with Interferon in Renal Cell Carcinoma18 x 10. U thrice weekly . There seems to be no significant difference in the response rates obtained by different IFNs: IFNα, EFNβ, natural leukocyte IFN, of recombinant IFN. Monotherapy with IFNγ has, however, been insufficiently evaluated in clinical studies. Due to the considerable interstud
烧烤
发表于 2025-3-24 12:32:30
http://reply.papertrans.cn/47/4624/462312/462312_17.png
jungle
发表于 2025-3-24 18:55:56
Monotherapy and Combination Therapy with Interferon-,, Interferon-,, and Tumor Necrosis Factor-, in have metastatic disease at the time of first presentation . The median survival for those patients is 6–12 months . Spontaneous regression of metastases after tumor nephrectomy is less than 1% . Hormonal treatment results in a small proportion (0%–10%) of objective responses, which are of
上腭
发表于 2025-3-24 22:12:12
http://reply.papertrans.cn/47/4624/462312/462312_19.png
出汗
发表于 2025-3-25 02:22:52
Combination Therapy of Renal Cell Carcinoma with Interleukin-2 and Interferon Alpha: The Cleveland Ce availability of these agents has rejuvenated the field of cancer immunotherapy, and clinical trials utilizing them have been performed with a variety of malignancies. Because renal cell carcinoma (RCC) is resistant to traditional systemic therapies and because earlier immunotherapy trials had sugg